Last reviewed · How we verify

Ultrasound-guided Suprascapular Nerve Block

Abant Izzet Baysal University · FDA-approved active Small molecule Quality 2/100

Ultrasound-guided Suprascapular Nerve Block is a Small molecule drug developed by Abant Izzet Baysal University. It is currently FDA-approved.

At a glance

Generic nameUltrasound-guided Suprascapular Nerve Block
SponsorAbant Izzet Baysal University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ultrasound-guided Suprascapular Nerve Block

What is Ultrasound-guided Suprascapular Nerve Block?

Ultrasound-guided Suprascapular Nerve Block is a Small molecule drug developed by Abant Izzet Baysal University.

Who makes Ultrasound-guided Suprascapular Nerve Block?

Ultrasound-guided Suprascapular Nerve Block is developed and marketed by Abant Izzet Baysal University (see full Abant Izzet Baysal University pipeline at /company/abant-izzet-baysal-university).

What development phase is Ultrasound-guided Suprascapular Nerve Block in?

Ultrasound-guided Suprascapular Nerve Block is FDA-approved (marketed).

Related